BP1223 / BrightPath Biotherap - LARVOL DELTA

BP1223, a Novel T Cell Engager Targeting CD39 for Potent Antitumor Activity in Acute Myeloid Leukemia (ASH 2024) - "BP1223 effectively depleted these CD39-positive blasts ex vivo, and this effect was further augmented by the combination with venetoclax and azacitidine, resulting in nearly complete depletion at clinically relevant concentrations. The minimal impact on normal bone marrow cells and endothelial cells underscores BP1223's high safety profile. These findings suggest that BP1223 could serve as a promising novel therapeutic option for AML, potentially improving outcomes in patients with CD39-expressing and chemotherapy-resistant disease."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ENTPD1 • PD-1

Preclinical Data for CD39-Targeted T Cell Engager BP1223 to be Presented at ASH 2024 [Google translation] (BrightPath Biotherapeutics Press Release) - "Key findings include: CD39 expression on AML blasts correlated with venetoclax resistance; BP1223, a CD39-targeting T cell engager created by our company using secondary specific antibody technology, demonstrated potent antitumor activity against CD39-positive and -negative AML blasts through T cell and bystander effects in clinical specimen studies; In addition, when administered in combination with standard chemotherapy venetoclax and azacitidine, near-complete eradication of AML blasts was observed; BP1223 had only minor effects on normal bone marrow cells and vascular endothelial cells; Administration of 0.1 mg/kg of BP1223 to AML xenograft models induced complete tumor regression in all treated mice (n=5); These data suggest that BP1223 represents a novel therapeutic approach for AML, including CD39-positive and chemotherapy-resistant cases."

Preclinical • Acute Myelogenous Leukemia